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OBJECTIVE — To evaluate the efﬁcacy, safety, and tolerability of pregabalin across the ef-
fective dosing range, to determine differences in the efﬁcacy of three times daily (TID) versus
twice daily (BID) dosage schedules, and to use time-to-event analysis to determine the time to
onset of a sustained therapeutic effect using data from seven trials of pregabalin in painful
diabetic peripheral neuropathy (DPN).
RESEARCH DESIGN AND METHODS — Data were pooled across seven double-
blind, randomized, placebo-controlled trials using pregabalin to treat painful DPN with dosages
of 150, 300, and 600 mg/day administered TID or BID. Only one trial included all three of these
dosages, and TID dosing was used in four. All studies shared fundamental selection criteria, and
treatment durations ranged from 5 to 13 weeks.
RESULTS — Pooled analysis showed that pregabalin signiﬁcantly reduced pain and pain-
related sleep interference associated with DPN (150, 300, and 600 mg/day administered TID vs.
placebo, all P  0.007). Only the 600 mg/day dosage showed efﬁcacy when administered BID
(P  0.001). Pain and sleep interference reductions associated with pregabalin appear to be
positively correlated with dosage; the greatest effect was observed in patients treated with 600
mg/day. Kaplan-Meier analysis revealed that the median time to onset of a sustained (30% at
end point) 1-point improvement was 4 days in patients treated with pregabalin at 600 mg/day,
5 days in patients treated with pregabalin at 300 mg/day, 13 days in patients treated with
pregabalin at 150 mg/day, and 60 days in patients receiving placebo. The most common treat-
ment-emergent adverse events were dizziness, somnolence, and peripheral edema.
CONCLUSIONS — Treatment with pregabalin across its effective dosing range is associated
with signiﬁcant, dose-related improvement in pain in patients with DPN.
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T
he prevalence of diabetic neuropa-
thyisashighas50%inpatientswho
have had diabetes for 25 years (1),
and painful diabetic peripheral neuropa-
thy (DPN) occurs in up to 26% of all peo-
ple with diabetes (2). Symptoms range
frommilddysesthesiastosevereunremit-
ting pain that can profoundly impact pa-
tients’ lives (3,4).
Medications of several different
classes are used to treat painful DPN with
varyingdegreesofefﬁcacy,safety,andtol-
erability. The antiepileptic agents gaba-
pentin and pregabalin have attained
widespreaduseinthetreatmentofpainful
DPN. These agents bind to the auxiliary
2- subunit of the voltage-sensitive cal-
cium channel, thereby decreasing Ca
2
inﬂux at nerve terminals and modulating
neurotransmitter release (5).
There are seven double-blind, ran-
domized, placebo-controlled trials in
painful DPN with pregabalin (6–12), ﬁve
ofwhicharepublishedinfull(7–11).The
effective dosing range for treatment of
neuropathic pain syndromes is 150 to
600 mg/day, administered either three
times daily (TID) or twice daily (BID).
Among the seven trials, dosages of 150,
300, and 600 mg/day were used, but only
one trial included all three of these dos-
ages. Thus, individually, the seven trials
present an incomplete picture of the ef-
fective dosing range. In addition, TID
dosing was used in the ﬁrst four trials,
whereas the three most recent trials of
pregabalin in painful DPN used BID
dosing.
The objective of the current report is
to use the pooled data from these seven
trials to evaluate the efﬁcacy, safety, and
tolerability of pregabalin across the effec-
tive dosing range. We also use these data
to determine differences in the efﬁcacy of
TID and BID dosing schedules. Finally,
we use a time-to-event analysis of the
pooleddatatodeterminethetimetoonset
ofasustainedtherapeuticeffectacrossthe
range of doses.
RESEARCH DESIGN AND
METHODS— Study treatment dura-
tionsrangedfrom5to13weeks(Fig.1A).
Four trials used TID dosing, three used
BIDdosing,andallbutonetrial(pregaba-
lin 300 mg/day vs. placebo) used escala-
tiontoassignedﬁxeddosingoveraperiod
of1to2weeks.Patientswererandomized
to placebo or ﬁxed-dosage pregabalin at
150, 300, or 600 mg/day. One trial in-
cluded a 75-mg/day dosage arm (8); re-
sults for this dosage are not presented
here, as 75 mg/day is considered to be a
nontherapeutic dosage of pregabalin in
painful DPN. One trial (10) studied both
DPN and postherpetic neuralgia patients
administered ﬂexible-dosage pregabalin
(150–600 mg/day), ﬁxed-dosage pre-
gabalin (600 mg/day), or placebo. To en-
sure consistency for the purposes of this
analysis, only the DPN patients who re-
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1448 DIABETES CARE, VOLUME 31, NUMBER 7, JULY 2008Figure 1—A: Dosage arms of seven trials contributing to this pooled analysis, ITT populations. *Trial used a modiﬁed ITT population: 11 patients
werewithdrawnbyMinistryofHealth/EuropeanCommitteeduringapartialclinicalhold.AEs,adverseevents;PBO,placebo;PGB,pregablin.†Trial
included 338 patients total, 96 of whom had painful DPN and were assigned to a ﬁxed dosage of 600 mg/day pregabalin. Postherpetic neuralgia
patients from this trial were not included in the present analysis nor were DPN patients assigned to ﬂexible-dosage pregabalin. ‡No dose escalation.
PBO, placebo. B: Pooled studies patient disposition with baseline demographics and characteristics.
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DIABETES CARE, VOLUME 31, NUMBER 7, JULY 2008 1449Figure 2—A: Change from baseline to end point in least-squares mean pain score based on last observation carried forward analysis. Patient
population comprised of patients who had both baseline and end point assessments (numbers in some groups are therefore smaller than in the ITT
population). Signiﬁcant reductions in end point least-squares mean pain score were observed for all three dosages investigated: 2.05, 2.36, and
2.75 points for patients receiving pregabalin 150, 300, and 600 mg/day vs. 1.49 for patients receiving placebo (*P  0.007 for 150 mg/day and
†P  0.0001 for 300 and 600 mg/day vs. placebo). B: Change from baseline to week 5 in least-squares mean pain score. Reductions were observed
forallthreedosagesinvestigated:1.98,2.44,and2.75pointsforpatientsreceivingpregabalin150,300,and600mg/dayvs.1.47forpatients
receiving placebo (*P  0.0001 vs. placebo; †P  0.01 vs. placebo). C: Proportion of patients meeting 50% improvement and 30% improvement
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the total cohort) were included in this
analysis.
Eachofthestudiessharedfundamen-
talinclusioncriteria,including18years
of age, an average pain score 4 (on an
11-point, Likert-like numeric rating scale
[NRS]: 0  “no pain” to 10  “worst pos-
sible pain”) over a 7-day baseline period,
andascore40mmonthe0-to100-mm
visual analog scale of the Short-Form
McGill Pain Questionnaire at screening
and randomization (baseline and ran-
domization in one study). All patients in
each trial were required to have A1C lev-
els 11%. Prior therapeutic failure of
gabapentin was an exclusion criterion
in three studies (6–8). All patients pro-
vided informed consent before partici-
pation, and all studies were conducted
in compliance with the ethics principles
originating in or derived from the Dec-
laration of Helsinki, internal review
board requirements, or good clinical
practices guidelines.
The primary efﬁcacy measure in each
study was end point mean pain score (on
the11-pointNRS)derivedfromentriesin
patients’ daily pain diaries. A supplemen-
tal responder analysis using two deﬁni-
tions of response—patients with 50%
and with 30% reductions in mean pain
scores from baseline—was also per-
formed. The studies included several sec-
ondary efﬁcacy measures. End point
mean sleep-interference score was de-
rivedfromdailysleepdiariesinwhichpa-
tients rated daily how much their pain
had interfered with their sleep (also done
using an 11-point NRS, with 0  “pain
does not interfere with sleep” to 10 
“pain completely interferes with sleep”).
Each study included the Patient Global
Impression of Change, in which pa-
tients rate their improvement on a
7-point scale ranging from “very much
worse” to “very much improved” (6–
12). These measures were also analyzed
to determine whether there were signif-
icant differences versus placebo be-
tween BID and TID dosing regimens.
Finally,timetoonsetofsustainedand
clinically meaningful pain relief was in-
vestigated across the seven studies. This
was deﬁned as the ﬁrst day on which pa-
tients demonstrated a 1-point reduc-
tion in mean pain score in patients with a
30 and 50% reduction in mean pain
scoreatendpoint.Thesetwocriteriawere
imposed to ensure clinically meaningful
and durable pain relief based on evidence
that in studies with a similar design, a
30% improvement from baseline corre-
sponds to a patient global impression of
change of “much improved” or “very
much improved” at study end point (13).
Baseline pain scores in a typical clinical
trial with painful DPN patients are be-
tween 6 and 6.5 on the 0- to 10-point
scale; therefore, a 30% improvement is
2 points. We deﬁned the “event” of in-
terest in this time-to-event analysis as the
timetotheﬁrst1-pointreductioninthe
daily pain score, recognizing that any
such criterion could be considered arbi-
trary. Time to onset of sustained pain re-
liefwasevaluatedbyapplyingtheKaplan-
Meier procedure, and comparisons with
placebo were made using the log rank
test.
Safety measures included incidence
of adverse events, physical and neuro-
logic examinations, 12-lead electrocar-
diogram, vital signs, weight change, and
clinicallaboratorytestingincludingA1C.
For the pooled analysis, all statistical
testing of efﬁcacy measures was per-
formed on the intent-to-treat (ITT) pop-
ulation. End point mean pain scores
using last observation carried forward
and sleep interference were analyzed
with ANCOVA (with a term for baseline
values and a term for treatment), whereas
other secondary efﬁcacy measures (re-
sponders) were analyzed using a logistic
regressionmodel(withatermforbaseline
values and a term for treatment).
RESULTS— A total of 1,510 patients
represented the ITT population in the
seven studies: 557 received placebo, and
953 received pregabalin. Ninety percent
of patients were white, and 58% were
male. Mean age was 59 years, mean
weightwas93kg,andmeanbaselinepain
score was 6.5 (Fig. 1B).
Efﬁcacy
Signiﬁcant reductions in end point least-
squares mean pain scores were observed
for all three dosages investigated (P 
0.007for150mg/dayandP0.0001for
300 and 600 mg/day vs. placebo) (Figs.
2A and B). Pain reductions associated
with pregabalin appear to be positively
correlated with dosage, with the greatest
effect observed in patients treated with
600 mg/day. The proportions of patients
experiencing50or30%reductionsin
pain levels (responders) were signiﬁ-
cantly greater in the pregabalin groups
than in the placebo group (Fig. 2C) and
were dose related.
The number needed to treat for these
data are as follows: pregabalin 600 mg/
day 4.04 (95% CI 3.3–5.3), pregabalin
300 mg/day 5.99 (4.2–10.4), and pre-
gabalin 150 mg/day 19.06 (CI for the ab-
solute risk reduction contains 0,
rendering the CI for the number needed
to treat difﬁcult to interpret).
More patients treated with pregabalin
reported global health status improve-
ments than patients treated with placebo,
as measured by the Patient Global Im-
pressionofChange.Eightypercentofpre-
gabalin 600 mg/day patients, 74% of 300
mg/day patients, and 65% of 150 mg/day
patients were improved, compared with
54% of placebo patients (300 and 600
mg/day, P  0.0001).
In each of the above analyses, both
BIDandTIDregimensof600mg/daypre-
gabalin were signiﬁcantly superior to pla-
cebo (P  0.0001 for all comparisons of
BID dosing to placebo and TID dosing to
placebo). For 300 mg/day, only the TID
frombaselineinmeanpainscoreatendpointbasedonlastobservationcarriedforwardanalysis.Patientpopulationiscomprisedofpatientswhohad
both baseline and end point assessments (numbers in some groups are therefore smaller than in the ITT population). Among patients receiving 150,
300, and 600 mg/day pregabalin, 27, 39, and 47%, respectively, reported pain reductions 50% from baseline to end point, while 22% of placebo
patientsreportedcomparablereductions(pregabalin300and600mg/day,†P0.0001vs.placebo).Usingthe30%improvementcriterion,alevel
ofimprovementdeemedclinicallymeaningful(31),43,55,and62%ofpatientstreatedwith150,300,and600mg/daypregabalin,respectively,were
responders vs. 37% of patients who received placebo (*P  0.0455 for 150 mg/day,
†P  0.0001 for 300, and ‡P  0.0001 for 600 mg/day vs.
placebo).D:Survivalcurveanalysisofthetimetoonsetofmeaningfulpainrelief,deﬁnedastheﬁrstdayonwhichpatientsdemonstratedasustained
1pointinmeanpainscorewheresustainedisdeﬁnedasa30%reductioninmeanpainscoreatendpoint.Themediantimetoonsetofasustained
(30% at end point) 1-point improvement was 4 days in patients treated with pregabalin at 600 mg/day, 5 days in patients treated with pregabalin
at 300 mg/day, 13 days in patients treated with pregabalin at 150 mg/day, and 60 days in patients receiving placebo. Hazard ratios were 1.44 for
pregabalinat150mg/day(P0.013),1.84forpregabalinat300mg/day(P0.0001),and2.26forpregabalinat600mg/day(P0.0001).PGB,
pregablin.
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to placebo (P  0.0001 for all compari-
sons); however, the 300 mg/day BID dos-
age group was included in only one of the
seven studies.
Kaplan-Meier analysis revealed that
the median time to onset of sustained
(30%improvementfrombaseline)pain
relief was 4 days in patients treated with
pregabalin at 600 mg/day, 5 days in pa-
tients treated with pregabalin at 300 mg/
day, 13 days in patients treated with
pregabalin at 150 mg/day, and 60 days in
patients receiving placebo (Fig. 2D).
Comparison of the pregabalin treatment
groups with placebo by log rank test con-
ﬁrmed that time to onset of clinically
meaningful pain relief was statistically
signiﬁcantly more rapid than with pla-
cebo (P  0.0001 for pregabalin doses of
300and600mg/dayandP0.01for150
mg/day).Themediantimetoonsetofsus-
tained (50% improvement from base-
line) pain relief was 6 days in patients
treated with pregabalin at 600 mg/day
and 12 days in patients treated with pre-
gabalinat300mg/day.Comparisonofthe
pregabalintreatmentgroupswithplacebo
by log rank test conﬁrmed that time to
onset of clinically meaningful pain relief
was statistically signiﬁcantly more rapid
than with placebo (P  0.0001 for pre-
gabalin doses of 300 and 600 mg/day and
P  NS for 150 mg/day).
Mean sleep interference scores at end
point were also signiﬁcantly improved in
all three pregabalin groups, with 150,
300,and600mg/dayshowingreductions
of 1.92, 2.32, and 2.62, respec-
tively, compared with 1.32 for placebo
(P  0.003 for 150 mg/day and P 
0.0001 for 300 and 600 mg/day vs. pla-
cebo).Aswithchangeinmeanpainscore,
improvement in sleep interference ap-
peared to be positively correlated with
dosage.
Safety and tolerability
Incidence of treatment-emergent adverse
events (TEAEs) appeared to be related to
dosage, with most of the common TEAEs
having the greatest incidence among pa-
tients receiving 600 mg/day (Table 1).
There was no consistent pattern in TEAE
incidence rates by dosing regimen, with
some TEAEs, such as peripheral edema
and weight gain, having greater incidence
in the BID dosing groups relative to the
TID dosing groups, while other TEAEs,
such as dizziness and somnolence, oc-
curred with greater frequency in the TID
than the BID groups. For all treatment
groups, TEAEs were generally mild to
moderate. The discontinuation rate due
to adverse events was greatest in the 600
mg/day group (Fig. 1B). Serious TEAEs
occurred in 3.4, 2.3, and 4.9% of patients
receiving 150, 300, and 600 mg/day pre-
gabalin and in 3.4% of patients receiving
placebo. The most common serious
TEAEs reported by both pregabalin and
placebo patients were of cardiovascular
nature and were not considered associ-
ated with treatment.
Over the course of 5 to 13 weeks of
treatment, the incidence of clinically
meaningful weight gain (deﬁned using a
Food and Drug Administration–guided
criterion of 7% weight increase from
baseline to end point) for pregabalin ver-
sus placebo was dose related: 2.01% for
pregabalinat150mg/day(P0.14[95%
CI 0.47 to 3.03%]), 2.12% for pregaba-
lin at 300 mg/day (P  0.04 [0.09 to
2.86%]),and3.88%forpregabalinat600
mg/day (P  0.0001 [1.76–4.54%])
groups,comparedwith0.73%forthepla-
cebogroup.Theoddsofweightgaincom-
pared with placebo are 2.3-fold for
pregabalin at 150 mg/day (P  0.14
[0.77–6.60%]), 2.8-fold for pregabalin at
300 mg/day (P  0.04 [1.06–7.47%]),
and6.2-foldforpregabalinat600mg/day
(P  0.0001 [2.82–13.67%]). Mean
changes in weight from baseline to end
point for pregabalin-treated patients ver-
sus placebo control subjects were 0.76 kg
for pregabalin at 150 mg/day (P  0.02
[0.08–1.11kg]),1.86kgforpregabalinat
300 mg/day (P  0.0001 [1.26–2.14
kg]), and 2.04 kg for pregabalin at 600
mg/day(P0.0001[1.54–2.22kg]);the
mean change was 0.16 kg for placebo.
The incidence of 7% weight gain by
studydurationacrossallpregabalindoses
is as follows: 5 weeks, 2.8%; 8 weeks,
6.8%; and 12–13 weeks, 7.9%.
There was a dose-related increase in
Table 1—Common TEAEs and discontinuations occurring in >5% of any treatment group (ordered by greatest percentage of adverse events
in the pregabalin 600 mg/day group)
Placebo
Pregabalin
150 mg/day 300 mg/day 600 mg/day
n (%) Discontinuation n (%) Discontinuation n (%) Discontinuation n (%) Discontinuation
n 557 176 266 511
Adverse event
Dizziness 26 (4.7) 0.7 12 (6.8) 1.1 62 (23.3) 3.4 142 (27.8) 6.8
Peripheral edema* 40 (7.2) 0.5 10 (5.7) 1.1 26 (9.8) 1.5 82 (16.0) 2.7
Somnolence 16 (2.9) 0.4 9 (5.1) 0.6 38 (14.3) 3.0 68 (13.3) 4.3
Weight gain 5 (0.9) 0 8 (4.5) 0 10 (3.8) 0.4 45 (8.8) 1.0
Asthenia 12 (2.2) 0.2 4 (2.3) 0.6 13 (4.9) 2.3 44 (8.6) 2.0
Headache 38 (6.8) 1.1 12 (6.8) 0.6 16 (6.0) 0.8 35 (6.8) 2.5
Dry mouth 7 (1.3) 0 3 (1.7) 0.6 13 (4.9) 0.8 30 (5.9) 1.8
Accidental injury 16 (2.9) 0 4 (2.3) 0 7 (2.6) 0.4 26 (5.1) 0.6
Vertigo 5 (0.9) 0.4 3 (1.7) 0 8 (3.0) 1.5 25 (4.9) 1.4
Nausea 29 (5.2) 0.9 4 (2.3) 0.6 8 (3.0) 1.1 23 (4.5) 2.0
Pain 18 (3.2) 0.4 9 (5.1) 0.6 8 (3.0) 0.4 20 (3.9) 0
Infection 35 (6.3) 0 14 (8.0) 0 23 (8.6) 0.8 17 (3.3) 0.4
Edema 0 0 4 (2.3) 0 13 (4.9) 0.4 10 (2.0) 0
Data are % unless otherwise indicated. *One patient in the 600-mg group had both edema and peripheral edema.
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The presence of edema across doses and
byseverityisasfollows:pregabalinat150
mg/day, mild 64.3%, moderate 28.6%,
and severe 7.1%; pregabalin at 300 mg/
day, mild 56.4%, moderate 41%, and se-
vere 2.6%; pregabalin at 600 mg/day,
mild 63.4%, moderate 33%, and severe
1.1%; and placebo, mild 81%, moderate
19%, and severe 0%.
In all pregabalin-treated groups,
15.2% had edema or peripheral edema,
6.0% had a 7% weight increase, and
2.3% had both weight increase and
edema. In comparison, in the placebo-
administered group, 7.3% had edema or
peripheral edema, 1.5% had a 7%
weight increase, and 0.2% had both.
There were no clinically meaningful
changes in laboratory values from base-
line to end point reported in the studies.
There were neither statistically signiﬁcant
nor clinically meaningful changes from
baseline to end point in A1C values (% of
total Hb) in pregabalin-treated patients
andincontrolsubjectsover5to13weeks
of treatment: pregabalin at 150 mg/day,
0.07% (95% CI 0.07 to 0.24); pregaba-
lin at 300 mg/day, 0.01% (0.01 to
0.26); pregabalin at 600 mg/day, 0.08%
(0.09 to 0.13); and placebo, 0.03%
(0.05 to 0.11).
CONCLUSIONS — In this pooled
analysis of patients with painful DPN
from seven randomized, controlled trials
spanning the effective dose range, pre-
gabalin was shown to signiﬁcantly reduce
pain associated with DPN. The pooled
analysis, in contrast to individual reports,
revealed efﬁcacy of the 150-mg dose;
however, efﬁcacy with BID dosing was
only present with the 600-mg dose. In
addition, time to event analysis revealed
that pregabalin was associated with a
dose-related, rapid onset of sustained
pain relief.
Several anticonvulsants with diverse
mechanisms of action have been sub-
jected to large-scale randomized con-
trolledtrialsassessingtherapeuticefﬁcacy
in the treatment of painful DPN. These
agents, which include topiramate (14–
16), lamotrigine (17), oxcarbazepine
(18,19), and gabapentin (20–22) have
shown varying efﬁcacy in clinical trials.
In contrast, pregabalin has shown ef-
ﬁcacyinsixofsevenclinicaltrials.Among
the seven trials, one included 150-, 300-,
and 600-mg/day treatment arms, two in-
cluded two of these dosages, and four in-
cluded only one of these dosages (Fig.
1A). Pooling data from all treatment arms
in this analysis adds to our knowledge of
theefﬁcacy,safety,andtolerabilityofpre-
gabalin for treatment of painful DPN. In
terms of efﬁcacy, there was an evident
dose response, with the greatest efﬁcacy
observedamongpatientstreatedwith600
mg/day. Equally evident from this pooled
analysis—but not from examination of
the trials individually, as 150 mg/day was
not signiﬁcantly efﬁcacious in any indi-
vidual study—was the observation that
patientstreatedwithpregabalinatitslow-
est effective dosage for chronic neuro-
pathic pain, 150 mg/day, experienced
statistically signiﬁcant improvements in
their pain and pain-related sleep interfer-
enceandrespondedtopregabalin(30%
improvement) in proportions signiﬁ-
cantly greater than placebo.
Time to onset analysis of the pooled
data revealed dose-related, rapid onset of
durable pain relief. By day 4, 50% of the
subjects taking 600 mg/day had a sus-
tained (30% at end point) 1-point im-
provementinpainscore,whilearesponse
of this magnitude was achieved by day 5
in the 300 mg/day group. All seven stud-
ies showed statistically signiﬁcant differ-
ences between pregabalin and placebo
by week 1 (6–10,12) or week 2 (11);
however, these analyses do not necessar-
ily imply that the response is clinically
meaningful. This approach also does not
provide insight into the durability of the
response in individual patients. Although
not frequently used in pain therapeutic
trials (23), the time to onset analysis used
hereprovidesnumericalandgraphic(Fig.
2D) information that is clinically relevant
for patient and clinician, speciﬁcally the
likelihood of a predetermined clinical re-
sponse (the hazard ratio) and the time to
this response. The analysis in this report
was complicated by the different dose es-
calation schedules of the individual stud-
ies. Since time to onset was determined
from the start of dose escalation and not
the time point when an effective thera-
peuticdosewasattained,theanalysismay
have overestimated the time to sustained
efﬁcacy. Future studies should incorpo-
rate this analytic technique prospectively.
The present analyses revealed that
dosing schedule (BID vs. TID) apparently
made no meaningful difference for pa-
tients treated with 600 mg/day, as both
regimens were highly statistically signiﬁ-
cant versus placebo. This ﬁnding is in
contrast to studies of postherpetic neural-
gia in which BID efﬁcacy was demon-
stratedacrossarangeofdosesfrom150to
600mg/day(24).Thebasisforthisdiffer-
ence in efﬁcacy between disease states is
not known, although it may be related, in
part, to the permitted use of concomitant
pain medication in all postherpetic neu-
ralgia pregabalin clinical trials (24–26).
However,the150-and300-mg/daydoses
were used BID in only one study in this
pooled analysis (15), and further studies
are required to deﬁnitively address this
question.
The dose-related increase in efﬁcacy
was accompanied by a dose-related in-
crease in incidence of most adverse
events. Similarly, the rate of discontinua-
tion due to an adverse event was dose
related. Dizziness, somnolence, and pe-
ripheral edema were the most common
adverse events. While there was a consis-
tent increase in the incidence of dizziness
acrossdoses,theincidenceofsomnolence
was similar in the 300- and 600-mg/day
doses. Examination of adverse events by
dosing regimen, i.e., BID versus TID, for
each pregabalin daily dosage did not re-
veal any consistent patterns favoring one
regimenovertheother.Therewasadose-
related increase in peripheral edema (Ta-
ble 1). Edema was not an exclusion
criterion in any study; however, clinical
judgmentiswarrantedwhenpregabalinis
used in patients with preexisting edema.
Pregabalinwasnotassociatedwithcardio-
vascular complications, rarely led to dis-
continuations, and was not associated
with laboratory changes suggestive of re-
nal or hepatic failure. The incidence of
reported weight gain was not only dose
related but also dependent on duration of
exposure. The underlying cause of the
weight gain is not known and does not
appear to be related to the presence of
peripheral edema. There was no evidence
that the weight increase compromised
glycemic control; the pooled analysis
showed no clinically meaningful changes
in A1C values in any dose cohort in stud-
ies with treatment durations of 5 to 13
weeks. Long-term studies are warranted
to address this question.
In conclusion, the current pooled
analysis of seven randomized, controlled
clinicaltrialsinpatientswithpainfulDPN
showed that over the effective dose range,
pregabalin not only signiﬁcantly reduced
pain associated with DPN but was also
associated with rapid onset of sustained
pain relief. The improvement in pain re-
lief was accompanied by a dose-related
incidence of adverse events.
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